Search Results
Sep 09, 2026, 15:35 ET 25 Years After 9/11, More FDNY Members Have Died from World Trade Center Illnesses Than Were Killed That Day.
campaign launches amid renewed national attention to 9/11's health legacy. Former Governor George Pataki disclosed this week that he has a 9/11-related lung disease, and newly released records show officials knew the air around Ground Zero was unsafe even as they publicly assured responders and residents
More news about: Firefighter Cancer Support Network
Sep 09, 2026, 14:28 ET Bitmine Immersion Technologies (BMNR) Công Bố Lượng ETH Nắm Giữ Đạt 5,93 Triệu Token, Đưa Tổng Tài Sản Tiền Mã Hóa và Tiền Mặt Lên Mức 15,7 Tỷ USD
liên kết tại đây) cho tháng 7 năm 2026. Tiêu đề của Thông Điệp này là "ETH chính là liều thuốc giải cho Thung Lũng Kỳ Lạ của Sự Giàu Có".Vào đầu năm 2026, Bitmine đã ra mắt MAVAN (Made in American VAlidator Network) – nền tảng staking chuyên biệt dành cho
More news about: Bitmine Immersion Technologies, Inc.
Sep 09, 2026, 12:38 ET /C O R R E C T I O N -- Altesa Biosciences Inc./
utilization, and lung function.About Altesa BioSciences, Inc.Altesa BioSciences is a clinical-stage pharmaceutical company led by global experts in respiratory medicine and infectious diseases. Altesa is dedicated to improving the lives of people with chronic lung diseases, including
More news about: Altesa Biosciences Inc.
Sep 09, 2026, 08:35 ET Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Sep 09, 2026, 08:25 ET Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
225Ac]Ac-FL-261 in the United States and Australia in patients with c-MET-expressing non-squamous non-small cell lung cancer ("nsNSCLC"). "These regulatory clearances represent an important milestone for FL-261 and our strategy to expand targeted alpha therapy
More news about: Full-Life Technologies
Sep 09, 2026, 08:00 ET Avo Expands MEDITECH Alliance Partnership, Bringing Its Suite of AI-Powered Products to MEDITECH's EHR
centerAvo solutions are used by over 35 MEDITECH customers including Berkshire Health Systems, Ozarks Healthcare, Moab Regional Hospital, Deborah Heart and Lung Center, and Pella Regional Health Center."Clinicians don't need more technology, they need technology that works together within their existing
More news about: AvoMD
Sep 09, 2026, 07:55 ET Brayton Purcell LLP Highlights Business Insurance Coverage of Growing Artificial Stone Silicosis Crisis
workers in their twenties to need lung transplants and kidney transplants."According to data from the California Department of Public Health (CDPH) referenced in the article, 635 patients have been identified with silicosis in California, 124 have required lung transplants, and 35 have died. Researchers
More news about: Brayton Purcell LLP
Sep 09, 2026, 07:00 ET Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development
invikafusp alfa's single-agent activity across eight distinct PD-1–resistant tumor types, including MSS colorectal cancer, PD-L1–negative non-small cell lung cancer and triple-negative breast cancer," said Zhen Su, M.D., MBA, President and Chief Executive Officer of Marengo Therapeutics. "The signals observed
More news about: Marengo Therapeutics
Sep 09, 2026, 06:12 ET American Lung Association Puts a Spotlight on Clinical Trials and How They Can Offer Hope to People Living With Lung Cancer
Learn more about lung cancer clinical trials here.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.
More news about: American Lung Association
Sep 08, 2026, 10:31 ET Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
Pharma's Efzofitimod is an innovative biologic immunomodulator under clinical development for interstitial lung disease (ILD), a group of immune-mediated conditions characterized by lung inflammation and fibrosis, or permanent scarring. Derived from a tRNA synthetase, efzofitimod selectively targets
More news about: DelveInsight Business Research, LLP
Sep 08, 2026, 09:00 ET Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysisSEOUL, South Korea, Sept. 8, 2026 /PRNewswire/
More news about: Lunit
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075. doi:10.1056/NEJMoa2307980/Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243. doi:10.1016/j.lungcan.2020.07.026.
More news about: Amgen
Sep 08, 2026, 08:17 ET HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
pharmacodynamic activity of HBM9378/WIN378 in patients with uncontrolled moderate-to-severe asthma. The study also evaluates the effects of HBM9378/WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total
More news about: Harbour BioMed
Sep 08, 2026, 08:00 ET Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image Analysis of Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Trial at ERS Congress
demonstrated that treatment with taladegib improved lung function from baseline as measured by forced vital capacity (FVC), increased total lung capacity and reversed measures of interstitial lung disease (ILD) from baseline at Week 12.Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered image
More news about: Brainomix
Sep 08, 2026, 08:00 ET Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
help educate families about protection against a serious respiratory syncytial virus (RSV) lung infectionBEYFORTUS has been chosen by millions of parents to help protect their babies from serious RSV lung infection, a leading cause of hospitalization among babies under 1 year of ageCampaign
More news about: Sanofi
Sep 08, 2026, 08:00 ET Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Acclaim-3 clinical trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program.Genprex's preclinical
More news about: Genprex, Inc.
Sep 08, 2026, 08:00 ET Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
pharmacodynamic activity of SKB378/WIN378 in patients with uncontrolled moderate-to-severe asthma. The study also evaluates the effects of SKB378/WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total
More news about: Kelun-Biotech
Sep 08, 2026, 07:30 ET Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
non-small cell lung cancer (NSCLC), with initial results targeted by mid-2027. This readout is expected to provide important clinical insights to inform future development, demonstrating the potential for INBRX-106 to extend well beyond head and neck cancer into not only perioperative lung cancer, but broader
More news about: Inhibrx Biosciences, Inc.
Sep 07, 2026, 21:00 ET Infinix ra mắt toàn cầu XPAD 30 Pro: Người bạn đồng hành tối ưu toàn diện cho việc học tập và giải trí của giới trẻ
hứng từ phong cách Bauhaus và Mondrian với lớp hoàn thiện cao cấp mang vẻ ngoài như kính. Ăng-ten ẩn giúp duy trì khả năng thu sóng mạnh mẽ trên mặt lưng kim loại bóng bẩy. Có ba phiên bản màu Twilight Purple, Anthracite Grey và Titanium Silver, máy tính bảng kết hợp vẻ đẹp nổi bật với độ bền vượt trội,
More news about: Infinix
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
China.About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis is a chronic, scarring lung disease characterized by progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis with a median survival
More news about: Insilico Medicine
Sep 05, 2026, 08:57 ET Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials
respiratory diagnostic technologies designed to make lung assessment faster, more comprehensive, and easier to perform. Its portable ALDS platform combines respiratory measurements with cloud-based analysis to support efficient, multidimensional lung-function assessment. ALDS PRO integrates airway oscillometry,
More news about: Signant Health
Sep 04, 2026, 17:05 ET Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3
More news about: Actinium Pharmaceuticals, Inc.
Sep 04, 2026, 10:30 ET Clinical Trials Services Market worth $97.41 billion by 2031 - Exclusive Report by MarketsandMarkets™
Contract Research Organization (CRO) Services Market Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area [Oncology (Breast, Lung), Infectious, Neurology, Vaccines], Modality, Model (FSO, FSP), End User, Competition - Global Forecast to 2031
More news about: MarketsandMarkets
Sep 04, 2026, 07:00 ET Withings Introduces StethO Sense, Bringing Heart and Lung Sound Analysis to BeamO
WorksFrom the StethO Sense section of the Withings+ app, users can select a heart or lung recording and instantly start the analysis. Heart recordings are taken at one of four standard positions, while lung recordings are taken at up to eight positions at 12 years of age and above, and six positions
More news about: Withings
Sep 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and
More news about: Insmed Incorporated